MLchartDataset catalogue

Resminostat

Term · Oncology and biomedicine · MLC-T-ONC-016501

An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.

Table 1. Record
IdentifierMLC-T-ONC-016501
FieldOncology and biomedicine
Synonymshistone deacetylase inhibitor 4SC-201; HDAC Inhibitor 4SC-201
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016501",
  "term": "Resminostat",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, inhibition of the transcription of tumor suppressor genes, inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.",
  "synonyms": [
    "histone deacetylase inhibitor 4SC-201",
    "HDAC Inhibitor 4SC-201"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/resminostat/"
}

Record 14,358 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.